University of Tennessee Graduate School of Medicine
Knoxville, Tennessee, 37920, United States
Location status: Recruiting
Location contact
Che A. Solla MD, MBA
PRINCIPAL_INVESTIGATOR
Study Coordinator: Lauren Crawford, MS
CONTACT
NCT Number: NCT07153614
The primary purpose of this study is to determine if intrathecal morphine (ITM) administration is superior to quadratus lumborum block or surgeon administered transversus abdominis plane (TAP) blocks result in decreased time to initiation of chemotherapy following oncologic surgery.
The secondary objectives of this study are to determine:
* The difference between interventions in time to return of bowel function in days * The difference between interventions in incidence of opioid related adverse drug events (ORADEs) * The difference between interventions in cumulative and post-operative total morphine milligram equivalents * The difference between interventions in quality-of-life assessment tool and patient satisfaction (brief pain index short form BPI-sf9) * The difference between interventions in hospital length of stay in days * The difference between cumulative pain scores between interventions * The difference between short acting and long-acting bupivacaine in pain management and time to chemotherapy
The hypothesis is that preoperative intrathecal morphine administration will significantly reduce the time to initiation of postoperative chemotherapy.
Interested in participating?
Request Info18 year–80 year
All sexes
Interventional
Not applicable
Knoxville, Tennessee, 37920, United States
Location status: Recruiting
Che A. Solla MD, MBA
PRINCIPAL_INVESTIGATOR
Study Coordinator: Lauren Crawford, MS
CONTACT
Enhanced recovery after surgery (ERAS) has become the standard of perioperative care for patients undergoing oncologic surgery. Multimodal and regional anesthetic techniques to reduce postoperative pain and opioid requirements are a key component of ERAS. Epidural analgesia was considered standard in early ERAS protocols. however, it is labor-intensive, requires close postoperative follow-up, and may exacerbate hemodynamic instability.
Long-acting intrathecal (IT) opioid use in oncologic surgery has been described as an equianalgesic technique to epidural analgesia with an improved safety profile, although both have the potential for neurological complications and respiratory depression9. Quadratus lumborum (QL) block is an alternative opioid sparing technique to neuraxial analgesia for abdominal surgery. QL blocks can provide similar pain coverage as an epidural with decreased hemodynamic instability. However, it is limited by its relatively short duration of effect, which ranges from 6 to 12 h. Another method employed is the transversus abdominis plane block. One of the advantages of this technique is that it does not depend on a separate service to perform like ITM and QL as it is commonly performed by the surgeon during surgery. However, unlike the QL block which has been shown to spread to the lumbar plexus and even thoracic paravertebral space providing both somatic and visceral analgesia, TAP blocks only provide somatic analgesia coverage. TAP blocks are still frequently performed by oncologic surgeons though the long term success compared to QL and ITM blocks is unclear. Most research looking into the efficacy of these techniques has been aimed at studying their effects on pain scores, opioid requirements, and opioid related adverse drug events.
Time to initiation of adjuvant chemotherapy (AC) following oncologic surgery is an important predictor of survivability that has not yet been considered in QL vs. IT comparison studies. Two meta-analyses demonstrated that postponing the postoperative AC was associated with poor survival in colorectal cancer patients. Results from Biagi et al. showed that every 4 weeks delay result in a 14% decrease of overall survival (OS). Similarly, Guetz's study indicated that delaying the initiation of AC for > 8 weeks after operation significantly decreased OS. In pancreatic and colorectal cancer, several factors are involved in this metric. One of the more common factors in this patient population is gastrointestinal complications including ileus. Some of these complications can be affected by perioperative opioid consumption.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Drugs/Device usage within 7 Days of Randomization if any:
Morphine 150 mcg
30 mL of 0.25% bupivacaine and 4mg of dexamethasone
Exparel-based solution mixed with 50mL of saline
Time frame: Day of surgery to first chemotherapy session, assessed on (Day 30, Day 60, Day 90 visits)
Time frame: From end of surgery up to 14 days postoperatively
Time frame: From baseline up to 90 days post-surgery
Time frame: From baseline up to 90 days post-surgery
Time frame: Post-op to discharge, assessed up to 30 days postoperatively
Time frame: Postoperatively at 1, 2, and 6 hours after surgery (Day 0); at 24 and 48 hours (Days 1 and 2); and on Days 7, 30, 60, and 90
Time frame: Post-op 14, 30, 60, and 90 days.
University of Tennessee Graduate School of Medicine
Other
Efficacy of Perioperative Opioid Sparing Techniques on Time to Initiation of Chemotherapy: A Randomized Single Blinded Control Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04912765
Adenocarcinoma, Carcinoma
Singapore
View Trial DetailsNCT06750094
Colonic Diseases, Colorectal Neoplasms
Chandler, Arizona, United States
View Trial DetailsNCT06662786
Colonic Diseases, Colorectal Neoplasms
Gilbert, Arizona, United States
View Trial DetailsNCT06411691
Colonic Diseases, Colonic Neoplasms
Baltimore, Maryland, United States
View Trial Details